Subgroup analyses revealed statistically significant between-subgroup differences for CRP (outcome measure, P = 0.004), DAPSA (drug, 0.003), HAQ (outcome measure, < 0.0001; drug, 0.001), psoriasis (outcome measure, 0.006; drug, 0.018), sex (outcome measure, < 0.0001), SJC (drug, 0.014), TJC (outcome measure, 0.036), and treatment line (outcome measure, 0.024). This evidence concerns the gene CRP and psoriasis.